
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
1 JULY - NDA Approvals for Calendar Year 2001 http://www.fda.gov/cder/rdmt/ndaaps01cy.htm
NDA Approvals for Calendar Year 2001http://www.fda.gov/cder/rdmt/ndaaps01cy.htm






